Boyapati A, et al. High Baseline Serum IL-6 Identifies a Subgroup of Rheumatoid Arthritis Patients with Rapid Joint Damage and Clinical Progression and Predicts Increased Sarilumab Treatment Response. ACR 2018, abstract L08.
Besluit over basispakket benadeelt patiënt
jun 2018 | Arthritis psoriatica, Osteoporose, RA